Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)

NCT02613819 is registered in ClinicalTrials.gov with Trans Tasman Radiation Oncology Group as lead sponsor.

NCT NCT02613819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)
Lead sponsor
Trans Tasman Radiation Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2016
Completion date
November 24, 2025
Enrollment
71 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma